Unliganded estrogen receptor α inhibits breast cancer cell growth through interaction with a cyclin-dependent kinase inhibitor (p21 WAF1)

FASEB Journal

Volumn 22, Issue 3, 2008, Pages 671-681

  Maynadier, Marie ^a,b   Ramirez, Jean Marie ^a,b   Cathiard, Anne Marie ^a,b   Platet, Nadine ^a,b   Gras, Delphine ^a,b   Gleizes, Michel ^b   Sheikh, M Saeed ^c   Nirde, Philippe ^a,b   Garcia, Marcel ^a,b,d  

^a INSERM   (France)

^b UNIV MONTPELLIER   (France)

^c State University of New York Upstate Medical University: College of Medicine   (United States)

^d CENTRE VAL D AURELLE   (France)

Author keywords

Cell cycle; Proliferation; Steroid

Indexed keywords

AMINO ACID; ANTIESTROGEN; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN E; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; MUTANT PROTEIN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; COMPLEX FORMATION; CONTROLLED STUDY; DNA BINDING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGAND BINDING; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CROSS LINKING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; THREE DIMENSIONAL IMAGING;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; LIGANDS; MICE; MICE, INBRED BALB C; MICE, NUDE; MUTATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; XENOGRAFT MODEL ANTITUMOR ASSAYS; ZINC FINGERS;

MUS MUSCULUS;

EID: 40449117681     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.07-9322com     Document Type: Article

References (48)

1. Gustafsson, J. A. (1999) Estrogen receptor β - a new dimension in estrogen mechanism of action. J. Endocrinol. 163, 379-383
2. Korach, K. S. (1994) Insights from the study of animals lacking functional estrogen receptor. Science 266, 1524-1527
3. Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schutz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., and Evans, R. M. (1995) The nuclear receptor superfamily: the second decade. Cell 83, 835-839
4. Gaub, M. P., Bellard, M., Scheuer, I., Chambon, P., and Sassone-Corsi, P. (1990) Activation of the ovalbumin gene by the estrogen receptor involves the Fos-Jun complex. Cell 63, 1267-1276
5. Paech, K., Webb, P., Kuiper, G. G., Nilsson, S., Gustafsson, J., Kushner, P. J., and Scanlan, T. S. (1997) Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 277, 1508-1510
6. Teyssier, C., Belguise, K., Galtier, F., and Chalbos, D. (2001) Characterization of the physical interaction between estrogen receptor α and JUN proteins. J. Biol. Chem. 276, 36361-36369
7. Stein, B., and Yang, M. X. (1995) Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-κB and C/EBPβ. Mol. Cell. Biol. 15, 4971-4979
8. Batistuzzo de Medeiros, S. R., Krey, G., Hihi, A. K., and Wahli, W. (1997) Functional interactions between the estrogen receptor and the transcription activator Sp1 regulate the estrogen-dependent transcriptional activity of the vitellogenin A1 io promoter. J. Biol. Chem. 272, 18250-18260
9. Weigel, N. L., and Zhang, Y. (1998) Ligand-independent activation of steroid hormone receptors. J. Mol. Med. 76, 469-479
10. Lippman, M., Bolan, G., and Huff, K. (1976) The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res. 36, 4595-4601
11. McGuire, W. L. (1978) Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin. Oncol. 5, 428-433
12. Fisher, B., Redmond, C., Fisher, E. R., and Caplan, R. (1988) Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J. Clin. Oncol. 6, 1076-1087
13. 3 receptor in breast cancer and relationship to prognosis. Cancer Res. 51, 239-244
14. Allred, D. C., Harvey, J. M., Berardo, M., and Clark, G. M. (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol. 11, 155-168
15. Hanrahan, E. O., Valero, V., Gonzalez-Angulo, A. M., and Hortobagyi, G. N. (2006) Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature. J. Clin. Oncol. 24, 2113-2122
16. Thompson, E. W., Paik, S., Brunner, N., Sommers, C. L., Zugmaier, G., Clarke, R., Shima, T. B., Torri, J., Donahue, S., Lippman, M. E., Martin, G. R., and Dickson, R. B. (1992) Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J. Cell. Physiol. 150, 534-544
17. Platet, N., Cunat, S., Chalbos, D., Rochefort, H., and Garcia, M. (2000) Unliganded and liganded estrogen receptors protect against cancer invasion via different mechanisms. Mol. Endocrinol. 14, 999-1009
18. Sisci, D., Aquila, S., Middea, E., Gentile, M., Maggiolini, M., Mastroianni, F., Montanaro, D., and Ando, S. (2004) Fibronectin and type IV collagen activate ERα AF-1 by c-Src pathway: effect on breast cancer cell motility. Oncogene 23, 8920-8930
19. Tora, L., Mullick, A., Metzger, D., Ponglikitmongkol, M., Park, I., and Chambon, P. (1989) The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties. EMBO J. 8, 1981-1986
20. Gossen, M., and Bujard, H. (1992) Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. U. S. A. 89, 5547-5551
21. Cayrol, C., and Ducommun, B. (1998) Interaction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21. Oncogene 17, 2437-2444
22. Karaiskou, A., Perez, L. H., Ferby, I., Ozon, R., Jessus, C., and Nebreda, A. R. (2001) Differential regulation of Cdc2 and Cdk2 by RINGO and cyclins. J. Biol. Chem. 276, 36028-36034
23. Sheikh, M. S., Rochefort, H., and Garcia, M. (1995) Overexpression of p21WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. Oncogene 11, 1899-1905
24. Glondu, M., Liaudet-Coopman, E., Derocq, D., Platet, N., Rochefort, H., and Garcia, M. (2002) Down-regulation of cathepsin-D expression by antisense gene transfer inhibits tumor growth and experimental lung metastasis of human breast cancer cells. Oncogene 21, 5127-5134
25. Prall, O. W., Carroll, J. S., and Sutherland, R. L. (2001) A low abundance pool of nascent p21WAF1/Cip1 is targeted by estrogen to activate cyclin E*Cdk2. J. Biol. Chem. 276, 45433-45442
26. Chambraud, B., Berry, M., Redeuilh, G., Chambon, P., and Baulieu, E. E. (1990) Several regions of human estrogen receptor are involved in the formation of receptor-heat shock protein 90 complexes. J. Biol. Chem. 265, 20686-20691
27. Mader, S., Chambon, P., and White, J. H. (1993) Defining a minimal estrogen receptor DNA binding domain. Nucleic Acids Res. 21, 1125-1132
28. Garcia, M., Derocq, D., Freiss, G., and Rochefort, H. (1992) Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. Proc. Natl. Acad. Sci. U. S. A. 89, 11538-11542
29. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K., and Elledge, S. J. (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805-816
30. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. (1993) p21 is a universal inhibitor of cyclin kinases. Nature 366, 701-704
31. 1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J. Biol. Chem. 272, 10882-10894
32. Osborne, C. K., Hobbs, K., and Clark, G. M. (1985) Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res. 45, 584-590
33. McCarty, K. S., Jr., Miller, L. S., Cox, E. B., Konrath, J., and McCarty, K. S., Sr. (1985) Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch. Pathol. Lab. Med. 109, 716-721
34. Dickson, R. B., and Lippman, M. E. (1995) Growth factors in breast cancer. Endocr. Rev. 16, 559-589
35. Henderson, B. E., Pike, M. C., and Casagrande, J. T. (1981) Breast cancer and the oestrogen window hypothesis. Lancet 2, 363-364
36. Kelsey, J. L., and Berkowitz, G. S. (1988) Breast cancer epidemiology. Cancer Res. 48, 5615-5623
37. Sasano, H., Sato, S., Ito, K., Yajima, A., Nakamura, J., Yoshihama, M., Ariga, K., Anderson, T. J., and Miller, W. R. (1999) Effects of aromatase inhibitors on the pathobiology of the human breast, endometrial and ovarian carcinoma. Endocr. Relat. Cancer 6, 197-204
38. Herynk, M. H., and Fuqua, S. A. (2004) Estrogen receptor mutations in human disease. Endocr. Rev. 25, 869-898
39. αΔ3) in breast cancer and the consequences of its reexpression: interference with estrogen-stimulated properties of malignant transformation. Mol. Endocrinol. 11, 2004-2015
40. Gu, Y., Turck, C. W., and Morgan, D. O. (1993) Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 366, 707-710
41. Zhang, H., Hannon, G. J., and Beach, D. (1994) p21-containing cyclin kinases exist in both active and inactive states. Genes Dev. 8, 1750-1758
42. Planas-Silva, M. D., and Weinberg, R. A. (1997) Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol. Cell. Biol. 17, 4059-4069
43. WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 97, 9042-9046
44. WAF1/Cip1 is an antiestrogen-regulated inhibitor of Cdk4 in human breast cancer cells. J. Biol. Chem. 277, 5145-5152
45. WAF1/CIP1 selectively controls the transcriptional activity of estrogen receptor alpha. Mol. Cell. Biol. 25, 2419-2430
46. Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ: relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status. Pathol. Int. 51, 94-99
47. WAF1 and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin. Cancer Res. 2, 1591-1599
48. Jiang, M., Shao, Z. M., Wu, J., Lu, J. S., Yu, L. M., Yuan, J. D., Han, Q. X., Shen, Z. Z., and Fontana, J. A. (1997) p21/WAF1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis. Int. J. Cancer 74, 529-534